The shareholders of Episurf Medical AB (publ) gathered in Stockholm, Sweden, Thursday 18 August 2016 for an Extraordinary General Meeting.
This information was published, 2016-08-18 15:53 CEST (GLOBE NEWSWIRE) —
Dennis D. Stripe and Wil Boren were elected as new members of the Board of Directors in addition to Saeid Esmaeilzadeh, Leif Ryd, Wilder Fulford and Christian Krüeger who were elected at the Annual General Meeting 2016. Dennis D. Stripe was elected as the new Chairman of the Board of Directors.
The Meeting resolved that each of the new members of the Board of Directors shall receive a fee of SEK 200,000, and that the Chairman of the Board of Directors shall receive a fee of SEK 400,000. No fees shall be paid for committee work.
Finally, the Meeting resolved in accordance with the proposal of the Board of Directors to adopt an employee stock option programme and to approve a directed issue of warrants to its subsidiary Episurf Operations AB, in order to ensure delivery of shares under the employee stock option programme. The employee stock option programme comprises not more than 151,600 employee stock options, corresponding after dilution to not more than approximately 0.9 per cent of the share capital and not more than approximately 0.7 per cent of the votes of the company. The programme includes (i) the managing director, who may be allotted 53,200 employee stock options, (ii) the CFO, who may be allotted 40,500 employee stock options, (iii) the COO, who may be allotted 33,900 employee stock options, and (iv) twelve other employees of the company in Sweden, who may be allotted 2,000 employee stock options each (these stock options will be allotted to persons within the company’s sales force).
Episurf Medical AB (publ)
The Board of Directors
For more information, please contact:
Rosemary Cunningham Thomas, CEO, Episurf Medical
Tel: +46 (0) 70-7655892
Tel: +44 (0) 7803-753603
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
Episurf Medical AB (publ) discloses the information provided herein pursuant to the Securities Market Act.